Drug intelligence / Profile preview

Measles-Rubella vaccine (Beijing Minhai Biotechnology)

Development stage: Unknown
Lead developer: Beijing Minhai Biological
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

The Measles-Rubella (MR) vaccine developed by Beijing Minhai Biotechnology is a live attenuated biologic vaccine designed for active immunization against measles and rubella viruses. It is indicated for the prevention of infections caused by these two pathogens. The vaccine works by eliciting a robust and protective immune response in the recipient. Beijing Minhai Biotechnology, founded in 2004, is the developer and manufacturer of this approved product. Clinical studies have demonstrated that the vaccine elicits robust protective immune responses with a favorable safety profile.

Other names: MR vaccineMeasles and rubella combined vaccine

Beyond the preview

Go deeper on Measles-Rubella vaccine (Beijing Minhai Biotechnology).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Measles-Rubella vaccine (Beijing Minhai Biotechnology).

Explore the full profile